循环生物标志物在肺动脉高压中的应用进展

Application Progress of Circulating Biomarkers in Pulmonary Hypertension

肺动脉高压(PH)由多种潜在疾病引起,病因复杂,导致患者生活质量和运动能力下降以及生存恶化。生物标志物对PH早期诊断、预后分层、调整治疗策略有重大意义,但其在不同类别PH中的应用各有利弊,至今尚缺乏可广泛用于各类PH的单一生物标志物。目前,临床上N端脑钠肽前体和心肌肌钙蛋白在PH中应用广泛,此外在各大研究中可溶性生长刺激表达基因2蛋白、心脏型脂肪酸结合蛋白、红细胞分布宽度、生长分化因子-15、新蝶呤、半乳凝素-3、微RNA、细胞外囊泡等生物标志物也显示出一定优势。

Pulmonary hypertension(PH)is caused by multiple underlying diseases and has a complex etiology that worsens quality of life,exercise capacity and survival.Biomarkers are of great significance for the early diagnosis of PH,the stratification of prognosis and the adjustment of treatment strategies.Nevertheless,their application in different categories of PH have own advantages and disadvantages,and there is no single biomarker that can be widely used in different categories of PH.Currently,N-terminal pro-brain natriuretic peptide and cardiac troponin are widely used in clinical PH.Besides,biomarkers such as soluble growth stimulation expressed gene 2,heart-type fatty acid-binding protein,red blood cell distribution width,growth differentiation factor-15,neopterin,galactin-3,microRNA and extracellular vesicles have also showed certain advantages in various researches.